Literature DB >> 29506424

Local recurrence rate in patients with colorectal cancer liver metastasis after wedge resection or percutaneous radiofrequency ablation.

Naïk Vietti Violi1, Rafael Duran1, Nicolas Demartines2, Christine Sempoux3, Boris Guiu1, Pierre E Bize1, Nathalie Sala3, Nermin Halkic2, Jean-Francois Knebel1,4, Alban Denys1.   

Abstract

PURPOSE: To compare local recurrence (LR) rate in patients with colorectal cancer liver metastasis (CRCLM) after surgical wedge resection (WR) or radiofrequency ablation (RFA) and to investigate predictive factors of LR.
MATERIALS AND METHODS: This single-centre, retrospective, institutional review board-approved study including 43 consecutive patients with 121 metastases treated by WR and 60 patients with 110 metastases treated by RFA between 2007 and 2014 with 23 and 18.5 months of follow-up, respectively. Demographics and tumour characteristics were compared using the unpaired t-test and chi-square test. Predictive factors for LR (lesion size, depth, relation to hepatic vessels, intervention, margin status) were investigated in uni- and multivariate analyses.
RESULTS: Patient and CRCLM characteristics were similar in both groups. Mean lesion size and depth in the WR and RFA groups were 18 mm and 15 mm (p = 0.03), and 19 mm and 26 mm (p < 0.001), respectively. LR showed a trend towards difference in favour of RFA (19% and 10% in the WR and RFA groups, respectively, p = 0.06). Positive margins and lesion depth were predictive factors of LR in the WR group (p = 0.03 and p = 0.02, respectively, on uni- and multivariable analyses). Lesion depth and proximity to a vein increased the risk of positive margins on pathology after WR (p = 0.04 and p < 0.001, respectively). Our analysis did not identify any predictive factors of LR following RFA.
CONCLUSION: Our study showed a trend towards a lower LR rate with RFA compared to WR. Lesions located deep in the liver and/or close to large vessels are at high risk of LR following WR, while curative treatment can be obtained with RFA.

Entities:  

Keywords:  Wedge resection; colorectal cancer; liver metastasis; local recurrence; radiofrequency ablation

Mesh:

Year:  2018        PMID: 29506424     DOI: 10.1080/02656736.2017.1372644

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  5 in total

1.  TMEM100 Modulates TGF-β Signaling Pathway to Inhibit Colorectal Cancer Progression.

Authors:  Huixia Li; Chuan Cheng; Weibo You; Jiujian Zheng; Jie Xu; Peng Gao; Jianping Wang
Journal:  Gastroenterol Res Pract       Date:  2021-08-11       Impact factor: 2.260

2.  Improved Outcomes of Thermal Ablation for Colorectal Liver Metastases: A 10-Year Analysis from the Prospective Amsterdam CORE Registry (AmCORE).

Authors:  Robbert S Puijk; Madelon Dijkstra; Bente A T van den Bemd; Alette H Ruarus; Sanne Nieuwenhuizen; Bart Geboers; Florentine E F Timmer; Evelien A C Schouten; Jan J J de Vries; Bram B van der Meijs; Karin Nielsen; Rutger-Jan Swijnenburg; M Petrousjka van den Tol; Kathelijn S Versteeg; Birgit I Lissenberg-Witte; Hester J Scheffer; Martijn R Meijerink
Journal:  Cardiovasc Intervent Radiol       Date:  2022-05-18       Impact factor: 2.797

3.  Ten-Year Outcomes of Percutaneous Radiofrequency Ablation for Colorectal Cancer Liver Metastases in Perivascular vs. Non-Perivascular Locations: A Propensity-Score Matched Study.

Authors:  Binbin Jiang; Hongjie Luo; Kun Yan; Zhongyi Zhang; Xiaoting Li; Wei Wu; Wei Yang; Minhua Chen
Journal:  Front Oncol       Date:  2020-10-16       Impact factor: 6.244

4.  Percutaneous Radiofrequency Ablation Combined With Chemotherapy Versus Chemotherapy Only for Ovarian Cancer Liver Metastasis.

Authors:  Chun-Xue Wu; Miao-Ling Chen; Hao Zhang; Jian-Jun Han
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

5.  Percutaneous Microwave Ablation Versus Open Surgical Resection for Colorectal Cancer Liver Metastasis.

Authors:  Qinxian Zhao; Zhigang Cheng; Zhiyu Han; Fangyi Liu; Xiaoling Yu; Xianliang Tan; Bin Han; Jianping Dou; Jie Yu; Ping Liang
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.